EGFR and cancer: Primary resistance, defined as the lack of initial responses to TKIs, has been observed in 20−30% of advanced EGFR‐mutant NSCLC patients,95 20−40% advanced ALK‐positive NSCLC patients,194 10% GIST patients,195 and other cancer patients.196